CEO of Chimerix, Inc. Michael T. Andriole Sells Shares

Chimerix, Inc. (NASDAQ:CMRX) has recently seen a significant transaction involving its Chief Executive Officer, Michael T. Andriole. On February 13th, Andriole sold 7,370 shares of the company's stock. The sale was completed at an average price of $4.52 per share, bringing in a total of $33,312.40. Following this transaction, Andriole's remaining stake in Chimerix comprises 609,603 shares, which is valued at approximately $2,755,405.56. This indicates a decrease of 1.19% in his shareholding position. Details of this transaction were disclosed through a filing made with the Securities and Exchange Commission (SEC), which can be accessed for further information.

Chimerix Stock Price Movement

On Friday, the CMRX stock experienced a drop of $0.18, resulting in a midday trading price of $4.38. The trading volume for the day amounted to 1,216,842 shares, while its average trading volume stands at 1,461,550. In terms of performance indicators, the 50-day simple moving average for the stock is reported at $3.46, and the 200-day simple moving average is at $1.79. Chimerix holds a market capitalization of $393.94 million, with a negative price-to-earnings (PE) ratio of -4.66 and a beta of 0.35. Over the past year, CMRX reached a low of $0.75 and a high of $4.65, highlighting its volatility in the market.

Insights from Wall Street Analysts

Several analysts on Wall Street have recently evaluated Chimerix stocks. Notably, Wedbush has reaffirmed an "outperform" rating with a price target of $6.00. Additionally, HC Wainwright has maintained a "buy" rating with a price target set at $11.00, reflecting optimistic perspectives on the company's future performance.

Institutional Investor Activity

Institutional investors have also shown interest in Chimerix, with various hedge funds making moves in the stock. Bender Robert & Associates acquired a fresh stake during the fourth quarter valued at $37,000. Furthermore, Susquehanna Fundamental Investments LLC purchased shares worth about $59,000, while Diadema Partners LP invested approximately $101,000. Stoneridge Investment Partners LLC raised its holdings by 22.5%, now owning 44,305 shares valued at $154,000 after acquiring an additional 8,134 shares. Charles Schwab Investment Management Inc. also took a new position in Chimerix during the fourth quarter, amounting to about $183,000. Institutions and hedge funds now collectively own 45.42% of the company's stock.

Overview of Chimerix, Inc.

Chimerix, Inc. is a biopharmaceutical company that focuses on developing treatments aimed at improving and extending the lives of patients dealing with severe diseases. The company's development pipeline includes ONC201, which is in advanced Phase 3 clinical trials targeting patients with H3 K27M-mutant diffuse glioma, and ONC206, a novel compound undergoing Phase 1 clinical trials for treatment in primary central nervous system tumors among both adult and pediatric populations.

Additional Reading

• Five stocks we like better than Chimerix
• Stock Ratings and Recommendations: Understanding Analyst Ratings
• NVIDIA’s Hidden AI Play
• When to Sell a Stock for Profit or Loss
• Three Fintech Stocks with Good Prospects
• Stocks with High Short Interest and Upside Potential

Chimerix, Stock, CEO